Curis, Inc. (NASDAQ: CRIS), a drug development company focused
developing next generation proprietary targeted medicines for cancer
treatment, today announced that the Company will be presenting at the
Merriman Curhan Ford 5th Annual Investor Summit
2008, which is being held on September 15-16, 2008 in San Francisco, CA.
Curis’ presentation will take place on Monday,
September 15th at 2:45 p.m. Eastern Daylight
Time (11:45 a.m. local time).
Daniel R. Passeri, Curis’ President and Chief
Executive Officer, will provide a presentation that includes an overview
of the status of GDC-0449, an orally-administered small molecule
inhibitor of the Hedgehog pathway that is currently in Phase II clinical
testing under collaboration with Genentech. Mr. Passeri will also
discuss CUDC-101, CUDC-305 and Curis’ other
targeted cancer programs in addition to other corporate activities.
There will also be a corresponding webcast of the presentation, which
can be accessed by visiting:
http://www.wsw.com/webcast/mcm10/cris/
The presentation will be archived shortly after the live event and
available for 30 days following the conference. In addition, it will
also be available for 30 days on the Investor Relations section of the
Curis website at www.curis.com.
About Curis, Inc.
Curis is a drug development company that is committed to leveraging its
innovative signaling pathway drug technologies to seek to create new
targeted small molecule drug candidates for cancer. In expanding its
drug development efforts in the field of cancer through its targeted
cancer drug development platform, Curis is building upon its previous
experiences in targeting signaling pathways for the development of next
generation targeted cancer therapies. For more information, visit Curis’
website at www.curis.com.
Curis, Inc.
Michael P. Gray, 617-503-6632
CFO & COO
mgray@curis.com
